ArticleAmerican journal of translational research2026
A comparative study on the efficacy of rituximab combined with tacrolimus and methylprednisolone in the treatment of patients with moderate-high risk idiopathic membranous nephropathy.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo compare the efficacy of combining methylprednisolone with either rituximab or tacrolimus for treating idiopathic membranous nephropathy (IMN).
methodThis research is designed as a prospective study (TCTR20260515001, URL: https://www.thaiclinicaltrials.org/show/TCTR20260515001). A total of 210 IMN patients treated at Binzhou People's Hospital from October 2021 to October 2024 were enrolled and randomly assigned to one of three groups: a control group, intervention group 1, and intervention group 2. The control group received methylprednisolone alone. Intervention group 1 underwent the same methylprednisolone therapy plus intravenous rituximab, while intervention group 2 received methylprednisolone combined with oral tacrolimus. General data, clinical efficacy after treatment, phospholipase A2 receptor (PLA2R), renal function indicators, inflammatory indicators, urinary immune indicators, quality of life, and adverse reactions were compared. Multivariate logistic regression analysis was used to examine whether the treatment regimen was an independent influencing factor for the patient's therapeutic effect. Subgroup analysis was used to compare the efficacy differences among patients with different characteristics after receiving different treatment plans.
resultsThe total effective rate of treatment in intervention group 1 was higher than that in intervention group 2 and the control group (P<0.05). With increasing treatment time, PLA2R, 24-hour urine protein quantification, serum creatinine (SCr), blood urea nitrogen (BUN), inflammatory indicators, and urinary immune indicators of all patients declined, and intervention group 1 exhibited lower values than both intervention group 2 and the control group (P<0.05); while plasma albumin (ALB) and Short Form-36 Health Survey score (SF-36) gradually increased with treatment time, and intervention group 1 exhibited higher values than intervention group 2 and the control group (
conclusionAfter adjusting for confounding factors such as age, diabetes, and baseline renal function, concurrent rituximab and methylprednisolone showed a more favorable therapeutic outcome compared to the tacrolimus regimen, and it was applicable to a wider range of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.